FrancophonIA/ELRC3.0 huggingface dataset:
English: Docetaxel Mylan is a ‘generic medicine'.
Slovenian: Docetaxel Mylan je „generično zdravilo“.
English: Docetaxel Mylan can be used on its own after other treatments have failed.
Slovenian: Zdravilo Docetaxel Mylan se lahko uporablja kot samostojno zdravilo, potem ko so se druge oblike zdravljenja izkazale kot neuspešne.
English: Docetaxel Mylan should be used in wards specialising in chemotherapy (medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Slovenian: Zdravilo Docetaxel Mylan je treba uporabljati na specializiranih oddelkih za kemoterapijo (zdravila proti raku) in se sme dajati le pod nadzorom zdravnika, usposobljenega za uporabo kemoterapije.
English: It can also be used with cisplatin (another anticancer medicine) in patients who have not yet received any treatment for their cancer;
Slovenian: Uporablja se lahko tudi sočasno s cisplatinom (drugim zdravilom proti raku) pri bolnikih, ki se zaradi raka še niso zdravili;
English: Docetaxel Mylan is used with cisplatin and 5-fluorouracil.
Slovenian: Zdravilo Docetaxel Mylan se uporablja sočasno s cisplatinom in 5-fluoroacilom.
English: The company also showed that the Docetaxel Mylan solution for infusion has comparable quality to that of Taxotere.
Slovenian: Poleg tega je predstavila tudi dokaze o tem, da je raztopina za infundiranje zdravila Docetaxel Mylan primerljive kakovosti kot zdravilo Taxotere.
English: Docetaxel Mylan is used with cisplatin and 5-fluorouracil (other anticancer medicines);
Slovenian: Zdravilo Docetaxel Mylan se uporablja sočasno s cisplatinom in 5-fluoroacilom (drugima zdraviloma proti raku);
English: Docetaxel Mylan is used with prednisone or prednisolone (anti-inflammatory medicines);
Slovenian: Zdravilo Docetaxel Mylan se uporablja sočasno s prednizonom ali prednizolonom (protivnetnima zdraviloma);
English: Why has Docetaxel Mylan been approved?
Slovenian: Zakaj je bilo zdravilo Docetaxel Mylan odobreno?
English: No additional studies were needed as Docetaxel Mylan is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.
Slovenian: Ker je zdravilo Docetaxel Mylan generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Taxotere, niso bile potrebne nobene dodatne študije.
English: What is Docetaxel Mylan used for?
Slovenian: Za kaj se zdravilo Docetaxel Mylan uporablja?
English: How has Docetaxel Mylan been studied?
Slovenian: Kako je bilo zdravilo Docetaxel Mylan raziskano?
English: How does Docetaxel Mylan work?
Slovenian: Kako zdravilo Docetaxel Mylan deluje?
English: How is Docetaxel Mylan used?
Slovenian: Kako se zdravilo Docetaxel Mylan uporablja?
English: Invented name Strength Pharmaceutical Form Route of administration Packaging
Slovenian: jakost farmacevtska oblika pot uporabe ovojnina
English: EU number
Slovenian: <Številka postopka EMEA> < Številka EU >
English: It is used in adults and adolescents aged over 12 years and who weigh at least 35 kg.
Slovenian: Uporablja se pri odraslih in mladostnikih, starih 12 let in več, s telesno maso vsaj 35 kg.
English: What measures are being taken to ensure the safe and effective use of Descovy?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Descovy?
English: Other information about Descovy
Slovenian: Druge informacije o zdravilu Descovy
English: The full EPAR for Descovy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Descovy je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The company also provided data from supporting studies including studies looking at the way Descovy was absorbed in the body.
Slovenian: Družba je predstavila tudi podatke iz podpornih študij, vključno s študijami, ki so proučevale, kako se je zdravilo Descovy absorbiralo v telesu.
English: The company therefore presented data from the studies previously used to approve Genvoya, including 2 studies in 1,733 previously untreated adults, where around 90% of patients responded to treatment, and another study showing benefit was maintained when patients treated with other effective combinations were switched to Genvoya.
Slovenian: Družba je zato predstavila podatke iz študij, ki so bile predhodno uporabljene za odobritev zdravila Genvoya, vključno z dvema študijama s 1 733 predhodno nezdravljenimi odraslimi, v katerih se je približno 90 % bolnikov odzvalo na zdravljenje, in drugo študijo, ki je pokazala, da so se koristi zdravila ohranile, če so bolniki, ki so se zdravili z drugimi učinkovitimi kombinacijami, prešli na zdravilo Genvoya.
English: It is not intended to provide practical advice on how to use Descovy.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: This is a summary of the European public assessment report (EPAR) for Descovy.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Descovy.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Descovy's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Descovy večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: A risk management plan has been developed to ensure that Descovy is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Descovy je bil pripravljen načrt obvladovanja tveganj.
English: Other common side effects include diarrhoea and headache.
Slovenian: Druga pogosta neželena učinka sta driska in glavobol.
English: It does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.
Slovenian: Okužbe z virusom HIV ali AIDS-a ne ozdravi, vendar pa lahko upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z AIDS-om.
English: What are the risks associated with Descovy?
Slovenian: Kakšna tveganja so povezana z zdravilom Descovy?
English: Why is Descovy approved?
Slovenian: Zakaj je bilo zdravilo Descovy odobreno?
English: Descovy is an antiviral medicine used in combination with other medicines to treat individuals infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Slovenian: Descovy je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi zdravili za zdravljenje posameznikov, okuženih z virusom človeške imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
English: The recommended dose is one tablet per day, and the strength of Descovy tablet chosen by the doctor depends on which other medicines it is given with.
Slovenian: Priporočeni odmerek je ena tableta na dan, jakost zdravila Descovy, ki jo izbere zdravnik, pa je odvisna od drugih zdravil, ki jih jemljete v kombinaciji z njim.
English: By blocking reverse transcriptase, Descovy reduces the amount of HIV in the blood and keeps it at a low level.
Slovenian: Zdravilo Descovy z zaviranjem reverzne transkriptaze zniža količino virusa HIV v krvi in jo ohranja na nizki ravni.
English: What benefits of Descovy have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Descovy izkazalo v študijah?
English: What is Descovy and what is it used for?
Slovenian: Kaj je zdravilo Descovy in za kaj se uporablja?
English: The most common side effect with Descovy (which may affect 1 in 10 people) is nausea (feeling sick).
Slovenian: Najpogostejši neželeni učinek zdravila Descovy (ki lahko prizadene 1 osebo od 10) je navzeja (slabost).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Descovy, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Descovy in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: They block the activity of reverse transcriptase, an enzyme made by the virus that allows it to reproduce itself in the cells it has infected.
Slovenian: Zavirata delovanje reverzne transkriptaze, tj. encima, ki ga ustvari virus in ki omogoča, da se virus razmnožuje v celicah, ki jih je okužil.
English: For the full list of all side effects and restrictions with Descovy, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Descovy glejte navodilo za uporabo.
English: Descovy emtricitabine / tenofovir alafenamide
Slovenian: Descovy emtricitabin/alafenamidtenofovirat
English: The active substances in Descovy (emtricitabine and tenofovir alafenamide) are already approved to treat HIV infection together with two other active substances (elvitegravir and cobicistat) as part of the combination medicine Genvoya.
Slovenian: Zdravilni učinkovini v zdravilu Descovy (emtricitabin in alafenamidtenofovirat) sta že odobreni za zdravljenje okužb z virusom HIV, skupaj s še dvema drugima zdravilnima učinkovinama (elvitegravir in kobicistat) kot del kombiniranega zdravila Genvoya.
English: Descovy contains tenofovir alafenamide which is effective at a lower dose than the established medicine tenofovir disoproxil and offers the possibility of reduced side effects.
Slovenian: Zdravilo Descovy vsebuje alafenamidtenofovirat, ki je učinkovit pri nižjih odmerkih kot uveljavljeno zdravilo dizoproksiltenofovirat in ponuja možnost zmanjšanja neželenih učinkov.
English: For more information about treatment with Descovy, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Descovy preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: For practical information about using Descovy, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Descovy naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: These studies showed that Descovy produces comparable levels of emtricitabine and tenofovir alafenamide in the body to Genvoya.
Slovenian: Te študije so pokazale, da je zdravilo Descovy proizvedlo primerljive ravni emtricitabina in alafenamidtenofovirata v telesu kot zdravilo Genvoya.
English: Descovy can only be obtained with a prescription and treatment should be started by a doctor experienced in managing HIV infection.
Slovenian: Izdaja zdravila Descovy je le na recept, zdravljenje pa mora uvesti zdravnik z izkušnjami z zdravljenjem okužb z virusom HIV.
English: Descovy is available as tablets, each containing 200 mg of emtricitabine and either 10 or 25 mg of tenofovir alafenamide.
Slovenian: Ena tableta vsebuje 200 mg emtricitabina in 10 ali 25 mg alafenamidtenofovirata.
English: How does Descovy work?
Slovenian: Kako zdravilo Descovy deluje?
English: Similarly to Genvoya, Descovy offers an alternative option to giving emtricitabine with tenofovir disoproxil
Slovenian: Podobno kot pri zdravilu Genvoya je tudi pri zdravilu Descovy nadomestna možnost, da se namesto emtricitabina daje dizoproksiltenofovirat.
English: How is Descovy used?
Slovenian: Kako se zdravilo Descovy uporablja?
English: Descovy contains the active substances emtricitabine and tenofovir alafenamide.
Slovenian: Zdravilo Descovy vsebuje zdravilni učinkovini emtricitabin in alafenamidtenofovirat.
English: This summary was last updated in 02-2010.
Slovenian: Povzetek je bil nazadnje posodobljen 02-2010.
English: It can only be used in patients who weigh more than 47 kg.
Slovenian: Jemljejo ga lahko le bolniki, ki tehtajo več kot 47 kg.
English: Ribavirin BioPartners is taken with food each day in two divided doses (morning and evening).
Slovenian: Zdravilo Ribavirin BioPartners se jemlje s hrano vsak dan v dveh deljenih odmerkih (zjutraj in zvečer).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ribavirin BioPartners to BioPartners GmbH on 6 April 2010.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Ribavirin BioPartners, veljavno po vsej Evropski uniji, odobrila družbi BioPartners GmbH dne 6. aprila 2010.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ribavirin BioPartners.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z zdravilom in priporočila glede pogojev uporabe zdravila Ribavirin BioPartners.
English: This document is a summary of the European Public Assessment Report (EPAR) for Ribavirin BioPartners.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ribavirin BioPartners.
English: Ribavirin BioPartners must never be used on its own but only together with peginterferon alfa 2b or interferon alfa 2b (other medicines used in
Slovenian: Zdravilo Ribavirin BioPartners se ne sme nikoli uporabljati samostojno, temveč samo v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b (drugim zdravilom, ki se uporablja za zdravljenje hepatitisa).
English: Ribavirin BioPartners can also be used in adults whose disease has come back after previous treatment or whose previous treatment
Slovenian: Zdravilo Ribavirin BioPartners se lahko prav tako uporablja pri odraslih, pri katerih se je bolezen ponovila po predhodnem zdravljenju ali pri katerih prejšnje zdravljenje ni bilo uspešno.
English: This means that Ribavirin BioPartners is similar to a ‘reference medicine' already authorised in the European Union (EU) called Rebetol.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Rebetol.
English: Because Ribavirin BioPartners is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Slovenian: Ker je zdravilo Ribavirin BioPartners generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: Other information about Ribavirin BioPartners:
Slovenian: Druge informacije o zdravilu Ribavirin BioPartners:
English: Treatment with Ribavirin BioPartners should be started and monitored by a doctor who has experience in the management of long-term hepatitis C. The dose of Ribavirin BioPartners is based on the patient's body weight, and ranges from three to seven tablets a day.
Slovenian: Zdravljenje z zdravilom Ribavirin BioPartners sme uvesti in spremljati le zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa C. Odmerek zdravila Ribavirin BioPartners je odvisen od bolnikove telesne mase in znaša od tri do sedem tablet na dan.
English: Ribavirin BioPartners is a ‘generic medicine'.
Slovenian: Ribavirin BioPartners je „generično zdravilo“.
English: Ribavirin BioPartners is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply.
Slovenian: Zdravilo Ribavirin BioPartners naj bi vplivalo na nastajanje ali delovanje virusne DNK in RNK, brez katerih virusi ne morejo preživeti ali se razmnoževati.
English: Ribavirin BioPartners on its own has no effect on eliminating the hepatitis C virus from the body.
Slovenian: Zdravilo Ribavirin BioPartners kot samostojno zdravilo nima nobenega učinka na odstranitev virusa hepatitisa C iz telesa.
English: What are the benefit and risk of Ribavirin BioPartners?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Ribavirin BioPartners?
English: The Committee recommended that Ribavirin BioPartners be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Ribavirin BioPartners odobri dovoljenje
English: The CHMP concluded that, in accordance with EU requirements, Ribavirin BioPartners has been shown to have comparable quality and to be bioequivalent to Rebetol.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Ribavirin BioPartners primerljivo raven kakovosti kot zdravilo Rebetol ter da mu je biološko enakovredno.
English: Because Ribavirin BioPartners is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Rebetol.
Slovenian: Ker je zdravilo Ribavirin BioPartners generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Rebetol.
English: Ribavirin BioPartners is a medicine that contains the active substance ribavirin.
Slovenian: Ribavirin BioPartners je zdravilo, ki vsebuje zdravilno učinkovino ribavirin.
English: The active substance in Ribavirin BioPartners, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues'.
Slovenian: Zdravilna učinkovina zdravila Ribavirin BioPartners, ribavirin, je protivirusna učinkovina, ki spada v razred nukleozidnih analogov.
English: Ribavirin BioPartners is used in patients who have not been treated before, as long as the liver is still working and hepatitis C virus can be found in the blood.
Slovenian: Zdravilo Ribavirin BioPartners se uporablja za zdravljenje bolnikov, ki predhodno še niso bili zdravljeni, če jetra še delujejo normalno in je v krvi prisoten virus hepatitisa C. Lahko se uporablja pri odraslih (starejših od 18 let), ki so okuženi tudi z virusom humane imunske pomanjkljivosti (HIV).
English: Ribavirin BioPartners is used to treat long-term hepatitis C (a disease of the liver due to infection with the hepatitis C virus) in patients aged three years and older.
Slovenian: Zdravilo Ribavirin BioPartners se uporablja za zdravljenje bolnikov, starih tri leta ali več, ki imajo kronični hepatitis C (bolezen jeter zaradi okužbe z virusom hepatitisa C).
English: The full EPAR for Ribavirin BioPartners can be found here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ribavirin BioPartners je na voljo tukaj.
English: Why has Ribavirin BioPartners been approved?
Slovenian: Zakaj je bilo zdravilo Ribavirin BioPartners odobreno?
English: For more information about treatment with Ribavirin BioPartners, read the Package Leaflet (also part of the EPAR).
Slovenian: Za več informacij o zdravljenju z zdravilom Ribavirin BioPartners preberite navodilo za uporabo Celotno evropsko javno poročilo o oceni zdravila (EPAR) za referenčno zdravilo je na voljo na spletni
English: What is Ribavirin BioPartners used for?
Slovenian: Za kaj se zdravilo Ribavirin BioPartners uporablja?
English: How has Ribavirin BioPartners been studied?
Slovenian: Kako je bilo zdravilo Ribavirin BioPartners raziskano?
English: How is Ribavirin BioPartners used?
Slovenian: Kako se zdravilo Ribavirin BioPartners uporablja?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ipreziv on 07 December 2011.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Ipreziv, veljavno po vsej Evropski uniji, odobrila dne 7. decembra 2011.
English: The full EPAR for Ipreziv can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ipreziv je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is available as tablets (20 mg, 40 and 80 mg).
Slovenian: Na voljo je v obliki tablet (20, 40 in 80 mg).
English: therefore allowing the blood vessels to widen.
Slovenian: zaradi česar se krvne žile razširijo.
English: What benefit has Ipreziv shown during the studies?
Slovenian: Kakšne koristi je zdravilo Ipreziv izkazalo med študijami?
English: What is the risk associated with Ipreziv?
Slovenian: Kakšna tveganja so povezana z zdravilom Ipreziv?
English: Other information about Ipreziv
Slovenian: Druge informacije o zdravilu Ipreziv
English: This is a summary of the European public assessment report (EPAR) for Ipreziv.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ipreziv.
English: The studies lasted between six and 56 weeks and the main measure of effectiveness was the change in the systolic blood pressure (blood pressure when the heart is contracting).
Slovenian: Študije so trajale od 6 do 56 tednov, glavno merilo učinkovitosti pa je bila sprememba sistoličnega krvnega tlaka (krvnega tlaka pri krčenju srca).
English: For more information about treatment with Ipreziv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Ipreziv preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: The effects of Ipreziv were first tested in experimental models before being studied in humans.
Slovenian: Učinki zdravila Ipreziv so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
English: Eight main studies involving over 6,000 patients with essential hypertension were carried out with Ipreziv.
Slovenian: Izvedenih je bilo osem glavnih študij z zdravilom Ipreziv, v katerih je sodelovalo več kot 6 000 bolnikov z esencialno hipertenzijo.
English: Ipreziv is taken by mouth and the usual recommended dose is 40 mg once a day.
Slovenian: Zdravilo Ipreziv se jemlje peroralno, običajni priporočeni odmerek pa je 40 mg enkrat na dan.
English: Ipreziv 40 and 80 mg was also more effective than ramipril (10 mg).
Slovenian: Zdravilo Ipreziv z odmerkoma 40 in 80 mg je bilo učinkovitejše tudi od ramiprila (10 mg).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ipreziv.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Ipreziv, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Side effects with Ipreziv are generally mild or moderate, with the most common side effect being dizziness.
Slovenian: Neželeni učinki zdravila Ipreziv so na splošno blagi ali zmerni, najpogostejši neželeni učinek pa je omotica.
English: Ipreziv is used in adults who have essential hypertension (high blood pressure).
Slovenian: Zdravilo Ipreziv se uporablja pri odraslih bolnikih z esencialno hipertenzijo (visokim krvnim tlakom).
English: The Committee decided that the benefits of Ipreziv are greater than its risks in patients with essential hypertension and recommended that it be given marketing authorisation.
Slovenian: Odbor je zaključil, da so koristi zdravila Ipreziv večje od z njim povezanih tveganj pri bolnikih z esencialno hipertenzijo, in priporočil, da se zanj odobri dovoljenje za promet.
English: The active substance in Ipreziv, azilsartan medoxomil, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Slovenian: Zdravilna učinkovina v zdravilu Ipreziv, medoksomilazilsartanat, je „antagonist receptorjev angiotenzina II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.